Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

– Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS Congress 2019 – – 74% reduction in the risk of relapse ...

March 24, 2010 — One year of maintenance risperidone administered at the initial therapeutic dose for acute schizophrenia is more effective at preventing relapse than dose reduction strategies and is ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from the pivotal ...

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a ...

New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC [*] patients Comprehensive immunogenicity data demonstrate TG4050’s ...

Sixty-seven patients with acute myeloid leukemia (AML; 19 complete remission [CR] 1, 14 CR 2, nine CR > 2, 25 in relapse) and 37 with acute lymphoid leukemia (ALL; 14 CR 1, eight CR 2, two CR > 2, 13 ...

PRINCETON, NJ, September 26, 2025 (EZ Newswire) -- Opioid addiction, including dependence on substances such as fentanyl and heroin, is widely acknowledged as a global public health and social safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Axsome Therapeutics’ AXS-05 achieved the ...

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics’s ...